150 related articles for article (PubMed ID: 2160191)
1. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
Hasinoff BB
Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191
[TBL] [Abstract][Full Text] [Related]
2. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
Hasinoff BB
Agents Actions; 1989 Mar; 26(3-4):378-85. PubMed ID: 2544086
[TBL] [Abstract][Full Text] [Related]
3. The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
Hasinoff BB
Drug Metab Dispos; 1990; 18(3):344-9. PubMed ID: 1974197
[TBL] [Abstract][Full Text] [Related]
4. The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
Hasinoff BB; Reinders FX; Clark V
Drug Metab Dispos; 1991; 19(1):74-80. PubMed ID: 1673425
[TBL] [Abstract][Full Text] [Related]
5. Inhibition and inactivation of NADH-cytochrome c reductase activity of bovine heart submitochondrial particles by the iron(III)-adriamycin complex.
Hasinoff BB
Biochem J; 1990 Feb; 265(3):865-70. PubMed ID: 2306220
[TBL] [Abstract][Full Text] [Related]
6. The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.
Hasinoff BB; Kala SV
Agents Actions; 1993 May; 39(1-2):72-81. PubMed ID: 8285144
[TBL] [Abstract][Full Text] [Related]
7. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
Vile GF; Winterbourn CC
Cancer Res; 1990 Apr; 50(8):2307-10. PubMed ID: 2156615
[TBL] [Abstract][Full Text] [Related]
8. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
Thomas C; Vile GF; Winterbourn CC
Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.
Hasinoff BB
Drug Metab Dispos; 1993; 21(5):883-8. PubMed ID: 7902252
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
Hasinoff BB
J Pharm Sci; 1994 Jan; 83(1):64-7. PubMed ID: 8138912
[TBL] [Abstract][Full Text] [Related]
11. Effects of Doxorubicin (Adriamycin) and [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)]propane (ICRF-187) on skeletal muscle protease activities.
Zima T; Tesar V; Richardson PJ; Mantle D; Preedy VR
Toxicol Appl Pharmacol; 2001 Mar; 171(3):135-40. PubMed ID: 11243912
[TBL] [Abstract][Full Text] [Related]
12. Adriamycin and its iron(III) and copper(II) complexes. Glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin.
Hasinoff BB; Davey JP
Biochem Pharmacol; 1988 Oct; 37(19):3663-9. PubMed ID: 2845993
[TBL] [Abstract][Full Text] [Related]
13. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.
Buss JL; Hasinoff BB
Agents Actions; 1993 Sep; 40(1-2):86-95. PubMed ID: 8147274
[TBL] [Abstract][Full Text] [Related]
14. The Adriamycin (doxorubicin)-induced inactivation of cytochrome c oxidase depends on the presence of iron or copper.
Hasinoff BB; Davey JP; O'Brien PJ
Xenobiotica; 1989 Feb; 19(2):231-41. PubMed ID: 2543148
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
16. Is ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] unusually reactive for an imide?
Sisco JM; Stella VJ
Pharm Res; 1992 Aug; 9(8):1076-82. PubMed ID: 1409381
[TBL] [Abstract][Full Text] [Related]
17. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane).
Hasinoff BB
Free Radic Res; 1995 Apr; 22(4):319-25. PubMed ID: 7633562
[TBL] [Abstract][Full Text] [Related]
18. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
19. Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex.
Demant EJ; Jensen PK
Eur J Biochem; 1983 May; 132(3):551-6. PubMed ID: 6852013
[TBL] [Abstract][Full Text] [Related]
20. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
